Galia Tiram

Tel Aviv University — Israel

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.8kcitations43works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Interference and Gene Delivery(11), MicroRNA in disease regulation(10), Nanoparticle-Based Drug Delivery(9), Advanced biosensing and bioanalysis techniques(8), Nanoplatforms for cancer theranostics(7)

Publications43 total

Abstract 2361: A PD1-antibody-attenuated IL-2 fusion protein activates immune cells leading to the inhibition of tumor growth in ex vivo human 3D tumor models
Cancer Research·2024
Abstract 4057: Beyond IL-2: The promise of anti PD-1-attenuated IL-2 fusion protein in cancer immunotherapy
Cancer Research·2024
Abstract 4031: P-selectin as an emerging target for the treatment of primary and secondary brain tumors
Cancer Research·2024
Abstract 2601: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
Cancer Research·2024
Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
Journal of Controlled Release·2024· 14 cited
Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment
Science Advances·2021· 164 citedOpen Access
Abstract 714: From cancer to COVID-19- development of a dendritic cell-targeted nano-vaccine for prevention and therapy of COVID-19
Cancer Research·2021· 1 cited
Abstract 2716: P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression
Cancer Research·2021
P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression
Nature Communications·2021· 75 citedOpen Access
Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches
Advanced Therapeutics·2020· 66 citedOpen Access
Melanoma: Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma (Adv. Therap. 8/2020)
Advanced Therapeutics·2020
Immune-mediated approaches against COVID-19
Nature Nanotechnology·2020· 346 citedOpen Access
Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma
Advanced Therapeutics·2020· 15 citedOpen Access
Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma
The FASEB Journal·2018· 15 citedOpen Access
PO-367 Brain microenvironment-secreted cytokines facilitate glioblastoma proliferation and invasion
ESMO Open·2018Open Access
PO-200 Prevention of melanoma brain colonisation by inhibiting cytokines secretion from activated astrocytes
ESMO Open·2018Open Access
Image-guided surgery using near-infrared Turn-ON fluorescent nanoprobes for precise detection of tumor margins
Theranostics·2018· 68 citedOpen Access
Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer
Nature Communications·2017· 96 citedOpen Access
Amphiphilic poly(α)glutamate polymeric micelles for systemic administration of siRNA to tumors
Nanomedicine Nanotechnology Biology and Medicine·2017· 17 cited
Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome
eLife·2017· 99 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Ronit Satchi‐Fainaro(43), Paula Ofek(21), Eilam Yeini(20), Anna Scomparin(18), Shiran Ferber(15), Anat Eldar‐Boock(14), Dikla Ben‐Shushan(14), Adva Krivitsky(12), Rachel Grossman(9), Zvi Ram(9), Marcelo Calderón(9), Sabina Pozzi(8), Rainer Haag(8), Ron Kleiner(6), Yulia Liubomirski(6), Asaf Madi(6), Jack Henkin(4), Eytan Ruppin(4), Yana Epshtein(4), Rachel Blau(4)